(Q37684218)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20116637%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

review article

1 reference

title

Optimizing iron chelation strategies in beta-thalassaemia major (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20116637%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20116637%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

author name string

John B Porter

series ordinal

1

1 reference

22 August 2017

1 December 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20116637%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20116637%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

volume

23 Suppl 1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20116637%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

page(s)

S3-7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20116637%20AND%20SRC:MED&resulttype=core&format=json

Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload

17 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2809%2970003-7

7 January 2021

Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2809%2970003-7

7 January 2021

Effect of transfusional iron intake on response to chelation therapy in beta-thalassemia major

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2809%2970003-7

7 January 2021

LPI-labile plasma iron in iron overload

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2809%2970003-7

7 January 2021

Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2809%2970003-7

7 January 2021

Deferiprone: New insight.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2809%2970003-7

7 January 2021

Deferiprone or deferoxamine vs. combination therapy in patients with beta-thalassemia major: a case study in Taiwan

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2809%2970003-7

7 January 2021

Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac IRON and the prevention of heart disease in thalassemia. The Protocol of the International Committee on Oral Chelators.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2809%2970003-7

7 January 2021

Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2809%2970003-7

7 January 2021

Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2809%2970003-7

7 January 2021

A randomized controlled 1-year study of daily deferiprone plus twice weekly desferrioxamine compared with daily deferiprone monotherapy in patients with thalassemia major

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2809%2970003-7

7 January 2021

A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2809%2970003-7

7 January 2021

Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2809%2970003-7

7 January 2021

Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2809%2970003-7

7 January 2021

Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2809%2970003-7

7 January 2021

Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2809%2970003-7

7 January 2021

Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2809%2970003-7

7 January 2021

10.1016/S0268-960X(09)70003-7

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20116637%20AND%20SRC:MED&resulttype=core&format=json

release_rxpllrbgnve55i63jntfe67rxy

17 January 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/rxpllrbgnve55i63jntfe67rxy

24 November 2022

mapped directly with Wikidata item

1 reference